Twist Bioscience Corporation updated earnings guidance for the full fiscal year 2024. For the year, Total revenue is expected to be in the range of $288 million to $293 million, growth of 18% to 20%, Gross margin is expected to be approximately 40% to 41% for fiscal 2024, an increase across the range and Loss from operations before taxes of approximately $189 million to $194 million, an increase from $180 million to $188 million provided previously.